WHO ICTRP trial
A Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas
EUCTR2018-001796-21-GB · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2018-001796-21-GB |
|---|---|
| Public title | A Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas |
| Scientific title | A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation |
| Primary sponsor | Forma Therapeutics, Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United States;France;Canada;Spain;Australia;United Kingdom;Korea, Republic of |
| Conditions | Advanced Solid Tumors and Gliomas with an IDH1 Mutation MedDRA version: 20.0 Level: PT Classification code 10018338 Term: Glioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA… |
| Interventions | Product Name: olutasidenib Product Code: FT-2102 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Not available Current Sponsor code: FT-2102 Other descriptive name: olutasidenib Concentration unit: mg milligram(s) Concentration… |
| Registration date | Jan 10, 2018 |
| Target size | 200 |
| Secondary IDs | 2102-ONC-102;139611 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: